Donald C. Arbitblit

Donald C. Arbitblit is a leader among plaintiffs’ attorneys in assessing the legal, medical, and scientific aspects of personal injury, mass torts, and environmental and toxic exposure litigation. Don has served on Plaintiffs’ Science/Expert Committees in several national cases and served on the Plaintiffs’ Steering Committee in the Actos bladder cancer injuries federal multidistrict litigation that settled in 2015 for $2.4 billion.

Don was a member of the trial team that won the first Actos bellwether trial in April 2014, including a $9 billion punitive damage award. Don was also Chair of the Epidemiology/Causation Subcommittee of the federal Vioxx litigation from 2005-2010, and he was a member of the trial team that won a plaintiffs’ verdict in that litigation in 2006. Between 1998 and 2014, Don has served on science and expert witness committees in the Actos, Yaz, Fen-Phen Diet Drug, Rezulin, Baycol, Vioxx, and Sulzer hip implant cases.

Don has specialized in toxic exposure and defective pharmaceutical cases for twenty-six years. From 1994 to 1998, Don was lead counsel for a certified class of women who were intentionally exposed to radioactive iron without their consent while receiving prenatal care at Vanderbilt University hospital in the 1940s. Settlement included $10.3 million and a formal apology from Vanderbilt University.

Don also played a leading role in California coordinated litigation arising out of the Sacramento River Spill of 1991; the release of a sulfuric acid cloud from the General Chemical plant in Richmond, California in 1993; and a 1995 toxic release from the Unocal refinery in Rodeo, California. These cases resulted in settlements of approximately $300 million.

Don has authored articles on environmental and pharmaceutical drug issues for Ecology Law Quarterly, Mealey’s Emerging Toxic Torts, and Hastings West-Northwest Journal of Environmental Law and Policy. Super Lawyers magazine has recognized Don as a Super Lawyer for Northern California ten times. He has lectured to attorneys on science issues in pharmaceutical defect litigation for the American Association of Justice in 2011 (Yaz) and 2013 (Actos).